DENTSPLY SIRONA

Dentsply Sirona, Inc. engages in the design, manufacture, sales and distribution of professional dental products and technologies. It operates through the following segments: Technologies and Equipment and Consumables. The Technologies and Equipment segments comprises dental technology, equipment and healthcare consumable products such as dental implants, laboratory dental products, computer-aided design and computer-aided manufacturing systems, imaging systems, treatment centers and consumable medical device products. The Consumables segment offers preventive, restorative, instruments, endodontic and orthodontic dental products. The company was founded in 1899 and is headquartered in Charlotte, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Dentsply Sirona (XRAY) exceeds Q4 expectations, focuses on innovation

Dentsply Sirona (XRAY) reported strong financial performance in Q4 2022, with a strategic focus on digitalization and innovation. Despite challenges in organic sales and supply chain constraints, the company aims for margin improvement and growth opportunities through investments and pricing strategies. Restructuring efforts and acquisitions are set to drive profitability and market share gains.

Dentsply Sirona reports robust Q1 growth, eyes digital innovation

Dentsply Sirona's strong Q1 performance driven by Consumables and Aligners segments.
Challenges include mixed regional performance and cautious outlook on equipment demand.
Opportunities lie in digitalization, DSO partnerships, and growth in China and EPS targets.
Overall, a positive outlook with strategic focus on innovation and customer experience.

Dentsply Sirona exceeds Q2 expectations, eyes growth amid challenges

Dentsply Sirona reported strong financial performance in Q2 2023, exceeding expectations and raising full-year outlook across key financial metrics.
The company's strategic focus on growth, profitability, and digitalization, coupled with investments in key regions and product innovation, positions it for sustained success.
While facing challenges in certain markets and operational areas, Dentsply Sirona remains optimistic about opportunities for growth, innovation, and value creation in the dental industry.
Overall, Dentsply Sirona's performance highlights operational strengths, market positioning, and a forward-looking approach to driving shareholder value and market expansion.

DENTSPLY SIRONA reports mixed Q3 results, focuses on innovation and growth

DENTSPLY SIRONA's Q3 performance showed mixed results with challenges in certain markets but strength in key segments like CAD/CAM and Aligners.
The company is focused on driving value through innovation, maintaining a commitment to long-term plans, and navigating external challenges with confidence.
Despite headwinds, DENTSPLY SIRONA remains within guidance range for the year, with a strategic focus on volume growth and market expansion opportunities.

DENTSPLY SIRONA anticipates double-digit EPS growth in 2024

DENTSPLY SIRONA's Q4 2023 performance showed growth in key segments, with strategic initiatives set for 2024 as an inflection year for double-digit EPS growth.
The company is focusing on innovation, SKU optimization, and operational efficiency to drive profitability and revenue growth.
Challenges lie in certain segments and the need for organic growth normalization by 2025, but opportunities exist in new product launches and margin expansion.
Overall, DENTSPLY SIRONA is poised for accelerated profitable growth, with 2024 expected to be a pivotal year for improved performance.

DENTSPLY SIRONA reports mixed Q1 performance amidst innovation focus

DENTSPLY SIRONA navigated challenges in Q1 with a focus on innovation, sustainability, and strategic updates. While facing headwinds in certain segments and markets, the company aims to capitalize on growth opportunities through product launches and strategic initiatives.

DENTSPLY Sirona navigates revenue decline with strategic restructuring plans

DENTSPLY Sirona's Q2 performance reflects revenue decline and margin contraction, prompting strategic restructuring and focus on customer-centric initiatives. While facing challenges from macroeconomic factors and restructuring impacts, the company aims to leverage opportunities in shareholder returns and market dynamics to drive growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Dentsply Sirona, Inc. engages in the design, manufacture, sales and distribution of professional dental products and technologies. It operates through the following segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment is engaged in designing, manufacturing, and selling dental technology and equipment products. The Essential Dental Solutions segment designs, manufactures, and sells value-added endodontic, restorative, and preventive consumable products. The Orthodontic and Implant Solutions segment designs, manufactures, and sells various digital implant systems and dental implant products. The Wellspect Healthcare segment designs, manufactures, and sells continence care solutions for management of both urinary and bowel dysfunction dental products. The company was founded in 1899 and is headquartered in Charlotte, NC.

RADNOR, PA / ACCESSWIRE / November 21, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) ("DENTSPLY"). On October 24, 2024, DENTSPLY issued a press release "announc[ing] the voluntary suspension of sales and marketing of its Byte Aligners and Impression Kits while the Company conducts a review of certain regulatory requirements related to these products," and that its "decision was made in consultation with the U.S. Food and Drug Administration (FDA).

Investigation of XRAY: Kessler Topaz Meltzer & Check, LLP Encourages DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Investors with Significant Losses to Contact the Firm

NEW YORK CITY, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DENTSPLY SIRONA Inc. - XRAY

RADNOR, PA / ACCESSWIRE / November 20, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) ("DENTSPLY"). On October 24, 2024, DENTSPLY issued a press release "announc[ing] the voluntary suspension of sales and marketing of its Byte Aligners and Impression Kits while the Company conducts a review of certain regulatory requirements related to these products," and that its "decision was made in consultation with the U.S. Food and Drug Administration (FDA).

Notice of Investigation of XRAY: Kessler Topaz Meltzer & Check, LLP Encourages DENTSPLY SIRONA Inc. (NASDAQ: XRAY) Investors with Significant Losses to Contact the Firm

RADNOR, PA / ACCESSWIRE / November 19, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) ("DENTSPLY"). On October 24, 2024, DENTSPLY issued a press release "announc[ing] the voluntary suspension of sales and marketing of its Byte Aligners and Impression Kits while the Company conducts a review of certain regulatory requirements related to these products," and that its "decision was made in consultation with the U.S. Food and Drug Administration (FDA).

XRAY Investigation Notification: Kessler Topaz Meltzer & Check, LLP Encourages DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Investors with Significant Losses to Contact the Firm

RADNOR, PA / ACCESSWIRE / November 18, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) ("DENTSPLY"). On October 24, 2024, DENTSPLY issued a press release "announc[ing] the voluntary suspension of sales and marketing of its Byte Aligners and Impression Kits while the Company conducts a review of certain regulatory requirements related to these products," and that its "decision was made in consultation with the U.S. Food and Drug Administration (FDA).

XRAY Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Investors with Significant Losses to Contact the Firm

RADNOR, Pa., Nov. 17, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DENTSPLY SIRONA Inc. (NASDAQ: XRAY) (“DENTSPLY”).

NASDAQ: XRAY Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages DENTSPLY SIRONA Inc. (NASDAQ: XRAY) Investors with Significant Losses to Contact the Firm

RADNOR, Pa. , Nov. 16, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DENTSPLY SIRONA Inc. (NASDAQ: XRAY) ("DENTSPLY").

NASDAQ: XRAY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages DENTSPLY SIRONA Inc. (NASDAQ: XRAY) Investors with Significant Losses to Contact the Firm

NEW YORK CITY, NY / ACCESSWIRE / November 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DENTSPLY SIRONA Inc. ("Dentsply Sirona" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply Sirona securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.

Bronstein, Gewirtz & Grossman, LLC Encourages DENTSPLY SIRONA Inc. (XRAY) Shareholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DENTSPLY SIRONA Inc. ("Dentsply Sirona" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply Sirona securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.

Bronstein, Gewirtz & Grossman, LLC Is Investigating DENTSPLY SIRONA Inc. (XRAY) And Encourages Shareholders to Connect

NEW YORK CITY, NY / ACCESSWIRE / November 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DENTSPLY SIRONA Inc. ("Dentsply Sirona" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply Sirona securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against DENTSPLY SIRONA Inc. (XRAY) And Encourages Shareholders to Reach Out

NEW YORK CITY, NY / ACCESSWIRE / November 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DENTSPLY SIRONA Inc. ("Dentsply Sirona" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply Sirona securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against DENTSPLY SIRONA Inc. (XRAY) and Encourages Shareholders to Learn More About the Investigation

Evaluate Dentsply's (XRAY) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Dentsply (XRAY) International Revenue Performance Explored

NEW YORK CITY, NY / ACCESSWIRE / November 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DENTSPLY SIRONA Inc. ("Dentsply Sirona" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply Sirona securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against DENTSPLY SIRONA Inc. (XRAY) and Encourages Investors to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / November 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DENTSPLY SIRONA Inc. ("Dentsply Sirona" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply Sirona securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.

DENTSPLY SIRONA Inc. (XRAY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / November 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DENTSPLY SIRONA Inc. ("Dentsply Sirona" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply Sirona securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.

Bronstein, Gewirtz & Grossman, LLC Is Investigating DENTSPLY SIRONA Inc. (XRAY) And Encourages Investors to Connect

DENTSPLY SIRONA Inc. (XRAY) Q3 2024 Earnings Call Transcript

DENTSPLY SIRONA's third-quarter results showcase strong top-line growth in the Essential Dental Solutions segment. However, the lowered outlook for fiscal 2024 is a cause of concern.

XRAY Q3 Earnings & Revenues Beat Estimates, 2024 Guidance Revised

Dentsply Sirona Inc. XRAY shares are trading lower on Thursday.

Dentsply Sirona Stock Sinks On Dismal 2024 Guidance, Blames Macroeconomic, Competitive Pressures And Weakened Demand

The headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Dentsply (XRAY) Reports Q3 Earnings: What Key Metrics Have to Say

NEW YORK CITY, NY / ACCESSWIRE / November 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DENTSPLY SIRONA Inc. ("Dentsply Sirona" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply Sirona securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.

Bronstein, Gewirtz & Grossman, LLC Encourages DENTSPLY SIRONA Inc. (XRAY) Stockholders to Inquire about Securities Investigation

Dentsply International (XRAY) came out with quarterly earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.49 per share a year ago.

Dentsply International (XRAY) Q3 Earnings and Revenues Beat Estimates

CHARLOTTE, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced its financial results for the third quarter of 2024.

Dentsply Sirona Reports Third Quarter 2024 Results

NEW YORK CITY, NY / ACCESSWIRE / November 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DENTSPLY SIRONA Inc. ("Dentsply Sirona" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply Sirona securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against DENTSPLY SIRONA Inc. (XRAY) And Encourages Investors to Reach Out

XRAY's third-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.

Should You Buy, Sell or Hold DENTSPLY SIRONA Before Q3 Earnings?

NEW YORK CITY, NY / ACCESSWIRE / November 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DENTSPLY SIRONA Inc. ("Dentsply Sirona" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply Sirona securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against DENTSPLY SIRONA Inc. (XRAY) And Encourages Stockholders to Reach Out

News for DENTSPLY SIRONA Stock (XRAY)